Security
Kazia Therapeutics Limited American Depositary Shares · KZIA
KZIANASDAQotherCurrentCIK 1075880Updated Nov 4, 2026
Name history
NOVOGEN LTD · through Nov 17, 2017
KZIA price & chart
Loading TradingView…
NASDAQ:KZIA on TradingView ↗About the company
We are an emerging oncology-focused biotechnology company that has a portfolio of development candidates, diversified across several distinct technologies, with the potential to yield first-in-class and best-in-class agents in a range of oncology indications. Our lead development candidate is paxalisib (formerly known as GDC-0084), a small-molecule, brain-penetrant inhibitor of the PI3K / Akt / mTor pathway, that is being developed as a potential therapy for glioblastoma, the most common and most aggressive form of primary brain tumour in adults, as well advanced breast cancer and as other forms of brain cancer. Our second asset is EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3, which we licensed from Evotec SE in April 2021.
In the news
Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities News provided by Kazia Therapeutics Limited Dec 02, 2025, 09:00 ET Share this article Share to X Share this article Share to X SYDNEY , Dec. 2, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA ) ↗
Seeking Alpha
Kazia gains as Guggenheim is latest to initiate at Buy on lead asset ↗
Kazia Therapeutics Limited (KZIA) Discusses Clinical and Corporate Updates With Focus on Paxalisib Programs in Breast and Colorectal Cancer - Slideshow ↗
Kazia Therapeutics Limited (KZIA) Discusses Clinical and Corporate Updates With Focus on Paxalisib Programs in Breast and Colorectal Cancer Transcript ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · AUDSource
Source
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossAUD | -20,702,000Source | -26,778,000Source | -20,465,180Source | -24,647,815Source |
| Cash flows from financing activities: | ||||
| Dividends paid | —Source | —Source | —Source | — |
| Additional Financial Items | ||||
| AdjustmentsForSharebasedPaymentsAUD | 653,000Source | 533,000Source | 1,159,000Source | 1,675,000Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsAUD | 310,000Source | -20,000Source | 46,000Source | -1,789,000Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesAUD | 0Source | 776,000Source | — | — |
| ProceedsFromIssuingSharesAUD | 11,770,000Source | 2,914,000Source | 12,972,000Source | 3,726,000Source |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesAUD | 0Source | 371,000Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Selling, General and Administrative ExpenseAUD | 8,720,000Source | 13,563,000Source | 8,583,000Source | 4,512,000Source |
| Total RevenueAUD | 42,000Source | — | — | — |
| Additional Financial Items | ||||
| ApplicableTaxRatenumber | 0.25Source | 0.25Source | 0.25Source | 0.25Source |
| BasicEarningsLossPerShareAUD/shares | -0.04Source | -0.1Source | -0.11Source | -0.19Source |
| DilutedEarningsLossPerShareAUD/shares | -0.04Source | -0.1Source | -0.11Source | -0.19Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesAUD | 653,194,000Source | 532,597,000Source | 1,159,125Source | 1,674,581Source |
| FinanceIncomeAUD | 72,000Source | 12,000Source | 22,000Source | 2,000Source |
| ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillAUD | 6,440,000Source | — | — | — |
| IncomeTaxExpenseContinuingOperationsAUD | -1,746,000Source | -271,000Source | -271,000Source | -368,000Source |
| NetForeignExchangeLossAUD | — | — | — | 0Source |
| OtherIncomeAUD | 1,787,000Source | 173,000Source | 1,000Source | 25,000Source |
| PostemploymentBenefitExpenseDefinedBenefitPlansAUD | 1,761,000Source | 2,161,000Source | 2,250,000Source | 1,664,000Source |
| PostemploymentBenefitExpenseDefinedContributionPlansAUD | 54,000Source | 88,000Source | 131,000Source | 138,000Source |
| ProfitLossAttributableToOwnersOfParentAUD | -20,702,000Source | -26,778,000Source | -20,465,000Source | -24,648,000Source |
| ProfitLossBeforeTaxAUD | -22,448,000Source | -27,049,000Source | -20,736,000Source | -25,016,000Source |
| ResearchAndDevelopmentExpenseAUD | 7,326,000Source | 17,380,000Source | 15,564,000Source | 20,252,000Source |
| RevenueFromInterestAUD | — | — | 0Source | — |
Offerings
Registration 333-294392
Registration 333-290598
Registration 333-292303
Registration 333-284606
Filing attachments
ea030587301ex99-1.htm · 6-K · 2026-09-22
Exhibit 99.1 Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders Clinical Milestone Expands Development of Paxalisib Beyond Oncology and Triggers $2 Million Payment to Kazia SYDNEY, Australia, September 22, 2026 - Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, …
Read attachment ↗ea030430701ex99-1.htm · 6-K · 2026-09-01
Exhibit 99.1 Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further Reduction Paxalisib Was Well Tolerated as Monotherapy and in Combination with Checkpoint Inhibition Kazia is Preparing to Advance Paxalisib Into a Phase 2 Cl…
Read attachment ↗ea030430701ex99-2.htm · 6-K · 2026-09-01
Exhibit 99.2 Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor Activity Three-Arm Expansion of the Ongoing TNBC Trial Will Evaluate Paxalisib Plus Fulvestrant, With Palbociclib, Versus Standard-of-Care First Patient Expected By Yea…
Read attachment ↗ea030382001ex99-1.htm · 6-K · 2026-08-31
Exhibit 99.1 Kazia Therapeutics Limited Announces Proposed Public Offering SYDNEY, Australia, August 27, 2026 - Kazia Therapeutics Limited (NASDAQ: KZIA) (“Kazia” or the “Company”), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that it has commenced a tranched registered public offering (the “ Offering ”) of (i) American Depositary Shares (“ADSs”), each rep…
Read attachment ↗ea030382001ex99-2.htm · 6-K · 2026-08-31
Exhibit 99.2 Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering SYDNEY, Australia, August 28, 2026 - Kazia Therapeutics Limited (NASDAQ: KZIA) (“Kazia” or the “Company”), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced the pricing of its previously announced tranched registered public offering (the “Offering”) of (i) 2,580,000 …
Read attachment ↗ea030368401ex99-1.htm · 6-K · 2026-08-27
Exhibit 99.1 Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer Durable Complete Metabolic Response Ongoing Since November 2025 All Evaluable Patients Demonstrated Reductions in Metastasis-Associated CTC Clusters and Terminally Exhausted T cells, With Median Reductions of 83% and 51% Respectively No Treatment-Related Serious Adverse Events Observed SYDNEY, Australia, August 27, 2026 - Kazia Therapeutics Limited (N…
Read attachment ↗